Nothing Special   »   [go: up one dir, main page]

ATE389022T1 - Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen - Google Patents

Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen

Info

Publication number
ATE389022T1
ATE389022T1 AT02727108T AT02727108T ATE389022T1 AT E389022 T1 ATE389022 T1 AT E389022T1 AT 02727108 T AT02727108 T AT 02727108T AT 02727108 T AT02727108 T AT 02727108T AT E389022 T1 ATE389022 T1 AT E389022T1
Authority
AT
Austria
Prior art keywords
recombinant proteins
protein
suspension
transfection
expression
Prior art date
Application number
AT02727108T
Other languages
English (en)
Inventor
Yves Durocher
Sylvie Perret
Phuong Pham
Amine Kamen
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE389022T1 publication Critical patent/ATE389022T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT02727108T 2001-05-07 2002-05-07 Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen ATE389022T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28879001P 2001-05-07 2001-05-07

Publications (1)

Publication Number Publication Date
ATE389022T1 true ATE389022T1 (de) 2008-03-15

Family

ID=23108658

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727108T ATE389022T1 (de) 2001-05-07 2002-05-07 Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen

Country Status (7)

Country Link
US (2) US10421950B2 (de)
EP (1) EP1390511B1 (de)
AT (1) ATE389022T1 (de)
AU (1) AU2002257440A1 (de)
CA (1) CA2446185C (de)
DE (1) DE60225545T2 (de)
WO (1) WO2002090533A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217566B2 (en) * 2003-03-24 2007-05-15 Invitrogen Corporation Attached cell lines
JP2006121995A (ja) * 2004-10-29 2006-05-18 Tokyo Medical & Dental Univ Ｅｂｎａ１変異体
US8551774B2 (en) 2005-03-17 2013-10-08 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene expression
ES2461591T3 (es) 2005-10-28 2014-05-20 F. Hoffmann-La Roche Ag Expresión de proteínas en células de roedor
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US20100159512A1 (en) * 2006-03-06 2010-06-24 Kurt Osther Method for the preparation of recombinant human thrombin and fibrinogen
US8076139B1 (en) 2006-05-19 2011-12-13 Leinco Technologies, Inc. Processes and compositions for transfecting Chinese hamster ovary (CHO) cells
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
CA2722835C (en) 2008-05-15 2018-11-27 National Research Council Of Canada Process, vectors and engineered cell lines for enhanced large-scale transfection
EP2297301A1 (de) * 2008-05-28 2011-03-23 U-Protein Express B.V. Verfahren zur herstellung von proteinen oder proteinfragmenten
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
CN103492418B (zh) 2011-03-31 2016-06-29 阿莱斯亚生物疗法股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
SG194473A1 (en) 2011-04-13 2013-12-30 Ca Nat Research Council EXPRESSION SYSTEM WITH SAR ELEMENT FROM IFNa2
EA034414B1 (ru) 2012-01-09 2020-02-05 Адс Терапьютикс Са Способ лечения тройного негативного рака молочной железы
CN104507969A (zh) 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 抗siglec-15抗体
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
EP3548890B1 (de) 2016-12-01 2024-03-27 Norbert Gretz Mittel und verfahren zur visualisierung von gewebestrukturen
FR3063730B1 (fr) 2017-03-09 2021-09-17 Centre Nat Rech Scient Composes-clips surfactants pour l'extraction et la stabilisation en solution de proteines membranaires
CN113025648B (zh) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Expi293细胞瞬时表达目标蛋白的方法及其应用
CN114410682B (zh) * 2022-02-08 2024-07-26 美康生物科技股份有限公司 一种293t细胞瞬时表达目标蛋白的方法及其应用
CN117265049A (zh) * 2023-09-12 2023-12-22 武汉爱博泰克生物科技有限公司 利用反应管培养细胞表达高通量重组抗体的方法及装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) * 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
AU704218B2 (en) * 1994-05-20 1999-04-15 Board Of Trustees Of The Leland Stanford Junior University An autonomous replication system for mammalian cells
WO1998037185A2 (en) 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
AU744680B2 (en) * 1997-06-19 2002-02-28 General Hospital Corporation, The Compact epstein-barr virus replicons
US6210922B1 (en) 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system

Also Published As

Publication number Publication date
WO2002090533A2 (en) 2002-11-14
WO2002090533A9 (en) 2002-12-27
US10421950B2 (en) 2019-09-24
EP1390511A2 (de) 2004-02-25
CA2446185A1 (en) 2002-11-14
CA2446185C (en) 2013-06-18
AU2002257440A1 (en) 2002-11-18
EP1390511B1 (de) 2008-03-12
US20200010808A1 (en) 2020-01-09
DE60225545T2 (de) 2009-04-02
US20050170450A1 (en) 2005-08-04
DE60225545D1 (de) 2008-04-24
US10858629B2 (en) 2020-12-08
WO2002090533A3 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
ATE389022T1 (de) Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen
CN103382505B (zh) 利用双荧光素酶报告基因检测启动子活性的方法
US20090087907A1 (en) Compositions and Methods for Growth of Pluripotent Cells
HUP0101136A2 (hu) Fehérjeexpresszió baculovírus-vektort alkalmazó expressziós rendszerben
US7794976B2 (en) Methods and materials for expression of a recombinant protein
AU560340B2 (en) Rennin from recombinant dna
EA199900875A1 (ru) Растения с изменённым ростом
DK1084230T3 (da) Regulering af hæmatopoietisk stamcelledifferentiering ved anvendelse af humane mesenkymstamceller
NO20022180D0 (no) Hematopoietisk differensiering av humane embryoniske stamceller
WO2000073421A3 (en) Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
CN110129365B (zh) 一种高效稳定瞬时表达重组蛋白的方法及其应用
RU2005123274A (ru) Среда для культивирования клеток без белков и без сыворотки
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DE69638314D1 (de) Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie
BRPI9916095B8 (pt) célula e linhagem de célula expressando uma proteína heteróloga
CN102453716B (zh) 猪骨骼肌特异性表达基因α-actin启动子的克隆及应用
Gu et al. Establishment and characterization of an immortalized renal cell line of the Chinese tree shrew (Tupaia belangeri chinesis)
EP1391509A1 (de) Menschliches kollagen produzierende transformierte seidenraupe
CN102016025B (zh) 用于用动物细胞大量生产源自外源基因的蛋白质的表达载体及其应用
CN104342454A (zh) 用于用动物细胞大量生产源自外源基因的蛋白质的表达载体及其应用
WO2023010084A2 (en) Gene editing systems comprising a nuclease and uses thereof
Søndergaard Drosophila cells can be grown to high cell densities in a bioreactor
Gao et al. Transfection and expression of exogenous gene in laying hens oviduct in vitro and in vivo
TWI316958B (de)
CA2409701A1 (en) Method for introducing a nucleic acid into a cell (transfection) by means of calcium phosphate, and transfected cell

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties